Basic Information
| LncRNA/CircRNA Name | XIST |
| Synonyms | NA |
| Region | GRCh38_X:73820651-73852753 |
| Ensemble | ENSG00000229807 |
| Refseq | NR_001564 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | doxorubicin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR etc |
| Sample | cell lines(MDA-MB-231,MDA-MB-231/ADM) |
| Expression Pattern | differential expressed |
| Function Description | Moreover, XIST overexpression promoted cell proliferation and inhibited apoptosis of doxorubicin-treated MDA-MB-231 cells by promoting ANLN expression. XIST silencing inhibited cell proliferation and promoted apoptosis of doxorubicin-treated MDA-MB-231/ADM cells by inhibiting ANLN expression. Luciferase reporter assay showed that XIST functioned as a competing endogenous RNA to repress miR-200c-3p, which controlled its downstream target ANLN. In conclusion, these data reveal that XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN. |
| Pubmed ID | 32198770 |
| Year | 2020 |
| Title | LncRNA XIST Promotes Chemoresistance of Breast Cancer Cells to Doxorubicin by Sponging miR-200c-3p to Upregulate ANLN |
External Links
| Links for XIST | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |